Adlai Nortye partners with Lilly, Merck KGaA on AN4035-cetuximab cancer trial
LLY•Adlai Nortye entered clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA to evaluate AN4035 with cetuximab in an ongoing global Phase I trial. Both companies will supply cetuximab free of charge to trial sites in specified countries.
1. Trial collaboration
The ongoing global Phase I trial is testing AN4035 alone or with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors. Eli Lilly will supply cetuximab at no cost to US trial sites, while Merck will provide it free of charge to trial sites in Australia and China.
